See more : Vodafone Group Public Limited Company (VOD) Income Statement Analysis – Financial Results
Complete financial analysis of NeoGenomics, Inc. (NEO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeoGenomics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- American Equity Investment Life Holding Company (AEL-PB) Income Statement Analysis – Financial Results
- K&K Superstore Southern Public Company Limited (KK.BK) Income Statement Analysis – Financial Results
- Quarterhill Inc. (QTRH.TO) Income Statement Analysis – Financial Results
- Akoya Biosciences, Inc. (AKYA) Income Statement Analysis – Financial Results
- PT. Mitra Adiperkasa Tbk (PMDKY) Income Statement Analysis – Financial Results
NeoGenomics, Inc. (NEO)
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 591.64M | 509.73M | 484.33M | 444.45M | 408.83M | 276.74M | 258.61M | 244.08M | 99.80M | 87.07M | 66.47M | 59.87M | 43.48M | 34.37M | 29.47M | 20.02M | 11.50M | 6.48M | 1.89M | 558.07K | 369.97K | 93.49K | 1.00K | 252.40K |
| Cost of Revenue | 347.04M | 321.83M | 297.27M | 258.56M | 211.99M | 149.48M | 138.30M | 133.70M | 56.05M | 46.36M | 34.73M | 33.03M | 24.06M | 18.59M | 14.25M | 9.35M | 5.52M | 2.76M | 1.19M | 576.87K | 481.59K | 189.96K | 0.00 | 74.29K |
| Gross Profit | 244.60M | 187.90M | 187.06M | 185.89M | 196.84M | 127.27M | 120.32M | 110.38M | 43.76M | 40.71M | 31.74M | 26.84M | 19.43M | 15.78M | 15.21M | 10.66M | 5.98M | 3.72M | 696.92K | -18.79K | -111.62K | -96.47K | 1.00K | 178.11K |
| Gross Profit Ratio | 41.34% | 36.86% | 38.62% | 41.83% | 48.15% | 45.99% | 46.52% | 45.22% | 43.84% | 46.76% | 47.75% | 44.83% | 44.68% | 45.92% | 51.63% | 53.27% | 52.00% | 57.39% | 36.97% | -3.37% | -30.17% | -103.18% | 100.00% | 70.57% |
| Research & Development | 27.31M | 30.33M | 21.87M | 8.23M | 8.49M | 3.00M | 3.64M | 4.65M | 4.20M | 2.69M | 2.44M | 2.28M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.41K | 0.00 | 0.00 |
| General & Administrative | 243.10M | 243.36M | 221.35M | 143.79M | 127.99M | 84.82M | 88.76M | 75.78M | 33.63M | 23.81M | 17.40M | 15.84M | 12.87M | 11.27M | 10.06M | 0.00 | 0.00 | 3.58M | 1.50M | 710.77K | 382.71K | 440.79K | 0.00 | 0.00 |
| Selling & Marketing | 70.84M | 67.32M | 62.59M | 47.86M | 47.35M | 29.40M | 24.54M | 23.91M | 11.56M | 12.00M | 8.73M | 7.50M | 6.96M | 7.48M | 6.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 313.04M | 310.68M | 283.94M | 191.66M | 175.34M | 114.22M | 113.30M | 99.69M | 45.19M | 35.81M | 26.12M | 23.34M | 19.84M | 18.75M | 16.94M | 11.55M | 9.12M | 3.58M | 1.50M | 710.77K | 382.71K | 440.79K | 8.08M | 1.12M |
| Other Expenses | 11.99M | -213.00K | -499.00K | 11.86M | -4.63M | 14.00K | -1.32M | 3.46M | 2.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 26.40K |
| Operating Expenses | 352.34M | 341.00M | 305.81M | 199.89M | 183.83M | 117.23M | 116.93M | 104.34M | 49.39M | 38.50M | 28.56M | 25.63M | 19.84M | 18.75M | 16.94M | 11.55M | 9.12M | 3.58M | 1.50M | 710.77K | 382.71K | 487.21K | 8.08M | 1.15M |
| Cost & Expenses | 699.38M | 662.84M | 603.08M | 458.44M | 395.82M | 266.70M | 255.23M | 238.05M | 105.44M | 84.85M | 63.29M | 58.66M | 43.89M | 37.33M | 31.20M | 20.90M | 14.65M | 6.34M | 2.69M | 1.29M | 864.30K | 677.16K | 8.08M | 1.22M |
| Interest Income | 16.90M | 6.08M | 3.14M | 3.06M | 3.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.91M | 1.51M | 5.08M | 7.02M | 3.71M | 6.23M | 5.54M | 10.00M | 854.00K | 929.00K | 989.00K | 1.15M | 768.00K | 710.00K | 532.39K | 308.52K | 0.00 | 325.63K | 196.80K | 0.00 | 41.43K | 207.31K | 0.00 | 0.00 |
| Depreciation & Amortization | 72.58M | 79.21M | 62.07M | 41.89M | 35.91M | 21.73M | 22.59M | 23.21M | 7.14M | 5.64M | 4.41M | 3.82M | 2.09M | 1.78M | 1.18M | 740.56K | 506.36K | 306.59K | 181.07K | 104.26K | 48.04K | -207.31K | 245.67K | 26.40K |
| EBITDA | -17.61M | -78.63M | 52.08M | 34.85M | 43.26M | 31.79M | 26.55M | 29.25M | 3.51M | 7.86M | 7.59M | 5.03M | 1.68M | -812.00K | -526.31K | -143.43K | -2.63M | 446.58K | -619.30K | -625.30K | -446.30K | -583.67K | -7.83M | -944.53K |
| EBITDA Ratio | -2.98% | -16.46% | 8.95% | 7.56% | 9.45% | 11.49% | 9.53% | 11.98% | 3.51% | 2.55% | 4.78% | 8.40% | 3.85% | -4.52% | -1.90% | -0.77% | -23.11% | 6.03% | -32.85% | -112.05% | -120.63% | -624.31% | -783,229.50% | -374.47% |
| Operating Income | -107.74M | -153.11M | -9.99M | -2.13M | 8.38M | 10.04M | 3.38M | 2.57M | -5.64M | 2.22M | 3.17M | 1.21M | -409.00K | -2.96M | -1.73M | -883.99K | -3.14M | 139.99K | -800.36K | -729.56K | -494.33K | -583.67K | -8.08M | -970.93K |
| Operating Income Ratio | -18.21% | -30.04% | -2.06% | -0.48% | 2.05% | 3.63% | 1.31% | 1.05% | -5.65% | 2.55% | 4.78% | 2.02% | -0.94% | -8.62% | -5.86% | -4.42% | -27.30% | 2.16% | -42.45% | -130.73% | -133.61% | -624.31% | -807,796.60% | -384.67% |
| Total Other Income/Expenses | 10.64M | -1.72M | 103.68M | -64.00K | -9.36M | -6.22M | -5.55M | -10.00M | 1.15M | -929.00K | -989.00K | -1.15M | -768.00K | -340.00K | -515.30K | -498.60K | -239.20K | -139.99K | -196.80K | -89.42K | 0.00 | 0.00 | 0.00 | 646.00 |
| Income Before Tax | -97.10M | -159.34M | -15.08M | -14.06M | 3.65M | 3.82M | -3.48M | -7.42M | -4.49M | 1.29M | 2.19M | 65.00K | -2.70K | -2.59M | -1.71M | -1.07M | -3.12M | 139.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -970.28K |
| Income Before Tax Ratio | -16.41% | -31.26% | -3.11% | -3.16% | 0.89% | 1.38% | -1.35% | -3.04% | -4.50% | 1.48% | 3.29% | 0.11% | -0.01% | -7.54% | -5.80% | -5.37% | -27.09% | 2.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -384.42% |
| Income Tax Expense | -9.13M | -15.09M | -6.73M | -18.23M | -4.36M | 1.18M | -2.64M | -1.70M | -1.95M | 157.00K | 152.00K | 1.15M | 768.00K | -740.00K | -34.18K | 180.15K | 214.94K | -111.94K | 196.80K | 89.42K | 41.43K | 214.16K | 0.00 | -1.29K |
| Net Income | -87.97M | -144.25M | -8.35M | 4.17M | 8.01M | 2.64M | -846.00K | -5.72M | -2.54M | 1.13M | 2.03M | 65.00K | -1.18M | -3.30M | -2.24M | -1.38M | -3.38M | -129.66K | -997.16K | -818.99K | -535.76K | -590.52K | -8.08M | -970.28K |
| Net Income Ratio | -14.87% | -28.30% | -1.72% | 0.94% | 1.96% | 0.95% | -0.33% | -2.34% | -2.54% | 1.30% | 3.06% | 0.11% | -2.71% | -9.61% | -7.61% | -6.91% | -29.38% | -2.00% | -52.89% | -146.75% | -144.81% | -631.64% | -807,796.60% | -384.42% |
| EPS | -0.70 | -1.16 | -0.07 | 0.04 | 0.08 | 0.03 | -0.01 | -0.07 | -0.04 | 0.02 | 0.04 | 0.00 | -0.03 | -0.09 | -0.06 | -0.04 | -0.11 | -0.01 | -0.04 | -0.04 | -0.04 | -0.14 | -2.14 | -1.24 |
| EPS Diluted | -0.70 | -1.16 | -0.07 | 0.04 | 0.08 | 0.03 | -0.01 | -0.07 | -0.04 | 0.02 | 0.04 | 0.00 | -0.03 | -0.09 | -0.06 | -0.04 | -0.11 | -0.01 | -0.04 | -0.04 | -0.04 | -0.14 | -2.14 | -1.24 |
| Weighted Avg Shares Out | 125.50M | 124.22M | 119.96M | 108.58M | 100.47M | 91.57M | 78.16M | 77.04M | 60.53M | 53.48M | 48.26M | 45.03M | 42.76M | 37.33M | 34.64M | 31.51M | 29.76M | 26.17M | 22.26M | 19.90M | 14.39M | 4.21M | 3.77M | 781.98K |
| Weighted Avg Shares Out (Dil) | 125.50M | 124.22M | 119.96M | 111.79M | 103.62M | 91.57M | 79.43M | 77.54M | 60.53M | 56.02M | 52.78M | 48.72M | 42.76M | 37.33M | 34.64M | 31.51M | 29.76M | 26.17M | 22.26M | 19.90M | 14.39M | 4.21M | 3.77M | 781.98K |
3 Best Breakout Stocks to Invest in for Superlative Returns
NeoGenomics, Inc. (NEO) Q1 2023 Earnings Call Transcript
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
3 Top Stocks Likely to Exceed Estimates This Earnings Season
NeoGenomics to Announce First Quarter 2023 Financial Results
5 Top Stocks Likely to Come Up With Earnings Beat
La Banque CIBC étoffe sa gamme de CDR en lançant 6 nouveaux tickers de CDR sur la NEO Bourse
CIBC Expands CDR Line-Up With Launch of 6 New CDR Tickers on the NEO Exchange
3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing
5 Best and Worst Performing Mid-Cap Stocks in February 2023
Source: https://incomestatements.info
Category: Stock Reports